maia stock: MAIA Biotechnology (MAIA) — company, pipeline and market snapshot

This article explains maia stock — the publicly traded common shares of MAIA Biotechnology, Inc. — covering company background, lead candidate THIO (ateganosine), clinical status, financial profile...

2024-07-11 08:24:00

By Ravi Clark

Article rating

4.4

108 ratings

Bitget offers a variety of ways to buy or sell popular cryptocurrencies. Buy now!

A welcome pack worth 6200 USDT for new users! Sign up now!

MAIA (stock)

maia stock refers to the publicly traded common shares of MAIA Biotechnology, Inc. (ticker: MAIA) listed on the NYSE American. MAIA Biotechnology is a U.S. clinical‑stage immuno‑oncology company focused on telomere‑targeting and immunogenic activation, with its lead candidate commonly referenced as THIO or ateganosine. As a clinical‑stage biopharma, MAIA has no approved commercial products and therefore does not generate product revenue; its operations center on drug discovery, clinical development and capital raises to fund trials and research.

Company overview

MAIA Biotechnology, Inc. is organized as a U.S. clinical‑stage biotechnology company focused on novel oncology therapeutics that aim to combine direct tumor biology modulation (telomere targeting) with immune activation. The company’s business model centers on discovering and advancing small molecule and biologic candidates from preclinical stages through human clinical trials, then pursuing regulatory pathways and commercial partnerships if clinical data support further development.

Incorporation and headquarters: MAIA is incorporated in the United States and operates from its corporate headquarters in the U.S. (see company filings and investor relations for the latest address and corporate form).
Therapeutic focus: the company concentrates on telomere biology and tumor immunogenicity; its lead program, THIO (ateganosine), is being tested primarily in non‑small cell lung cancer (NSCLC) and in combination with PD‑(L)1 agents in second‑ or later‑line settings.
Business model: preclinical and clinical R&D, sponsored clinical trials, collaborations/partnerships and capital markets financing to support development until potential partnering or commercialization.

MAIA is a clinical‑stage enterprise and depends on equity financings, institutional investors, and collaborations to fund its pipeline activities.

History

MAIA’s corporate timeline includes its founding and early research phases, followed by a U.S. market listing, clinical milestones and periodic financing rounds. Key themes in the company history are: formation and early research, advancement of THIO into clinical testing, the company’s public listing on the NYSE American (previously NYSE MKT/NYSE American tiering in market data feeds), management and board appointments to lead clinical and commercial strategy, and discrete capital raises to support clinical work.

Listing: MAIA shares trade under the ticker MAIA on the NYSE American. Historical records show the company moved through public market milestones to list on that exchange.
Management: MAIA has publicly filed executive and board appointments in SEC filings and press releases; management backgrounds typically combine drug development, clinical operations and capital markets experience.
Strategic shifts: like many small biotech firms, MAIA has periodically adapted its strategy—focusing investment on lead assets (THIO/ateganosine), pursuing combination immuno‑oncology approaches, and exploring non‑traditional treasury approaches (see Corporate strategy & notable initiatives below).

For a precise chronology of dates (founding, IPO/listing, financing closings and clinical milestones) consult MAIA’s SEC filings and archived press releases.

Products and pipeline

MAIA’s pipeline is anchored by THIO, also referenced as ateganosine in public materials. The company describes THIO as a molecule with a proposed dual mechanism of action:

Telomere targeting: THIO is designed to interact with telomere biology in tumor cells, which can disrupt tumor cell proliferation or survival in susceptible cancers.
Immunogenic activation: THIO is reported to increase tumor immunogenicity and synergize with checkpoint inhibitors; the intended approach is combining THIO with PD‑(L)1 inhibitors to improve response rates in specific settings.

Primary indication focus:

Non‑small cell lung cancer (NSCLC) — second‑/later‑line settings and combination therapy with PD‑(L)1 agents.

Other assets:

MAIA may maintain early‑stage or preclinical programs that complement the lead asset. Public materials and investor disclosures list any non‑lead programs; for up‑to‑date pipeline tables consult the company’s investor relations materials and SEC disclosures.

Clinical strategy:

MAIA’s development plan for THIO typically emphasizes early‑phase dose‑finding, safety and signal identification (Phase 1/2) and expanding cohorts to explore combinations with immune checkpoint inhibitors. The company has signaled combination strategies and intends to evaluate THIO’s activity in immune‑sensitive tumor types.

Clinical development and regulatory status

MAIA’s THIO program has progressed through early clinical studies and cohort expansions designed to evaluate safety and preliminary efficacy. Publicly disclosed trial activity and regulatory communications include the following general points (for specific trial identifiers, cohort sizes and readouts see clinicaltrials.gov entries and company press releases):

Trial phases: THIO has been evaluated in Phase 1 and Phase 2 (or Phase 1/2) study designs with dose escalation and expansion cohorts. The company has disclosed interim data and cohort updates in press releases and conference presentations.
Enrollment and updates: the company provides enrollment status updates for cohorts and planned expansions; these appear in periodic press releases and investor presentations.
Efficacy and safety: interim signals (objective responses, disease control rates, biomarker correlations) and safety observations have been reported by the company in presentations and releases. Such interim findings are descriptive and early‑stage; they do not constitute confirmatory evidence of clinical benefit.
Regulatory milestones and designations: any formal regulatory designations (e.g., Fast Track, Breakthrough Therapy) or trial approvals are typically disclosed in company filings and press statements. As of the date of this article, consult the company’s press releases and SEC filings for any named designations.
Scientific dissemination: MAIA has presented clinical findings at oncology conferences and may have peer‑reviewed publications or abstracts; conference presentations are a common way for small biotech firms to share early clinical data.

Readers should consult clinicaltrials.gov, the company’s SEC filings and conference programs for the latest trial identifiers, enrolment status, and data summaries.

Financials

Clinical‑stage biotechnology companies like MAIA do not generate product revenue and therefore report operating losses while advancing clinical programs. MAIA’s financial profile emphasizes research and development expenses, general and administrative costs, and cash burn driven by trial activity.

Revenue and profitability

MAIA is unprofitable and reports net losses driven by R&D and administrative spending. As a clinical‑stage company, MAIA’s reported results typically show:

No product revenue from marketed drugs.
Net operating losses each reporting period while clinical trials are ongoing.
A reported cash burn that the company places in context of its runway and capital strategy in periodic filings.

For exact figures for revenue, net loss and R&D expense, consult the company’s most recent Form 10‑Q or Form 10‑K filed with the U.S. Securities and Exchange Commission (SEC).

Balance sheet and liquidity

MAIA’s balance sheet items that readers commonly track are cash and cash equivalents, short‑term investments (if any), debt and liabilities. The company periodically conducts financing transactions to maintain liquidity for clinical development. In addition, MAIA has publicly disclosed (via filings or press releases) strategic treasury policies in recent periods that include authorization to hold certain digital assets under defined limits; see Corporate strategy & notable initiatives.

Funding history

MAIA’s funding history includes one or more of the following: private placements, registered direct offerings, PIPEs (private investment in public equity), convertible notes, and at‑the‑market (ATM) issuances. Participation by insiders or board members in private placements has been disclosed when applicable. Specific dates, amounts and terms are reported in SEC filings (Form 8‑K, 10‑Q) and in company press releases.

For precise funding amounts and closing dates, see the company’s SEC filings and investor relations announcements.

Stock market information

Ticker and exchange

Ticker symbol: MAIA
Primary exchange: NYSE American (data feeds and some vendors may show alternate identifiers or suffixes in certain systems).

When monitoring the maia stock price, market participants can find quotes on major market data providers and in official exchange feeds for the NYSE American.

Note: if you use a cryptocurrency or Web3 wallet for research or custody of digital assets referenced in MAIA’s treasury disclosures, Bitget Wallet is recommended in Bitget‑branded materials for Web3 wallet needs; Bitget exchange is the promoted trading venue for digital asset work in Bitget content.

Trading history and market data

Trading characteristics for a small‑cap clinical biotech such as MAIA typically include relatively low daily trading volume compared with large‑cap equities, higher volatility around clinical announcements and financings, and a market capitalization that can fluctuate substantially with price moves and share issuance.

Quantified market snapshots (example public market data points):

As of January 27, 2026, a NYSE American trading snapshot in widely distributed market lists showed MAIA with a last trade near $2.56 and a trading volume of 371,792 shares in that session (AP / NYSE American intraday listing). Another NYSE American snapshot on the same date showed MAIA with a last trade near $2.35 and session volume of 215,694 shares in a different intraday listing. These figures are drawn from published exchange activity lists and press distribution on that date.

Small‑cap biotech market behavior notes:

Float and shares outstanding: small cap biotechs may have a relatively limited public float; details are available from company filings and market data providers.
Volatility: news flow (trial data, clinical reads, regulatory updates, financings) often drives day‑to‑day volatility more than broad market moves.

For up‑to‑date market cap, float and volume statistics see market data providers and the company’s filings.

Analyst coverage and price targets

MAIA may have limited sell‑side analyst coverage given its small‑cap clinical‑stage status. Coverage, when present, tends to be sparse and can vary in quality; independent research platforms and quant‑model services may provide grades or sentiment metrics. Investors and researchers should review the methodology behind any price targets or ratings and reconcile them with the company’s clinical timeline and reported cash runway.

Corporate strategy and notable initiatives

MAIA’s corporate strategy combines R&D execution for its lead program with capital management to support trials. Notable strategic elements include:

Focus on combination immuno‑oncology: prioritizing clinical evaluation of THIO with PD‑(L)1 inhibitors to assess potential synergistic benefit.
Partnership potential: seeking collaborators or licensing partners for specific indications, combination development or commercialization rights if clinical results warrant.
Capital strategy: periodic equity raises and other financing mechanisms to maintain trial funding.
Digital‑asset treasury initiative: in a recent corporate disclosure and supporting filings/press releases, MAIA announced a policy authorizing the company to hold certain regulated digital assets (examples disclosed in company materials include BTC, ETH and USDC) as a portion of its liquid assets subject to board approval and policy limits. This initiative was publicized in company materials and covered by data providers and news outlets.

As of January 27, 2026, the company’s digital‑asset treasury policy and any subsequent asset purchases or holdings should be verified in the company’s most recent SEC filings and investor communications.

Ownership, insiders and institutional holders

Ownership concentration in small‑cap biotech companies can be meaningful to stock behavior. Relevant points about MAIA ownership include:

Insider ownership: MAIA has disclosed director and executive shareholdings and any material insider transactions in SEC forms (Form 4) and company filings. Insider purchases or participation in private placements are typically reported.
Institutional holders: institutional ownership may be limited versus larger biotech names; major institutional holders (if any) and percentage stakes appear in quarterly proxy statements and in data provider summaries.

To review the latest ownership table and insider transactions, inspect the company’s most recent proxy materials and Form 4 filings.

Recent news and developments

Below is a timeline‑style summary of recent, material items concerning MAIA and maia stock. Dates reflect the public reporting timeframe; readers should verify the latest details with company releases and SEC filings.

Clinical updates and data releases: MAIA has issued interim clinical results, cohort updates and safety summaries for THIO cohorts in press releases and at conference presentations. These updates often drive intraday share movement and trading volume spikes.
Conferences and presentations: MAIA has presented clinical data at oncology symposia; abstracts, slides and program listings are available via conference organizers and the company’s investor relations materials.
Financing events: the company has completed equity financings and private placements in recent periods to extend operating runway; the company discloses these transactions in Form 8‑K and related filings.
Digital‑asset treasury announcement: as reported in company filings and press releases and summarized by financial data outlets, MAIA announced authorization to hold certain regulated digital assets as part of a treasury strategy. As of January 27, 2026, the disclosure was public; confirm current holdings and policy limits in the company’s latest filings.
Market listings and intraday trades: widely distributed market activity lists on January 27, 2026 showed maia stock trading on the NYSE American with session snapshots listing last trades of $2.56 (volume 371,792) and $2.35 (volume 215,694) in different intraday distribution points. These snapshots are reproduced in market feeds and press listings for that trading date.

For a comprehensive event list, consult the company’s press release archive and the SEC EDGAR record.

Risks and controversies

Investing in or following maia stock involves general and company‑specific risks typical of early‑stage biotechnology companies. Important risk categories include:

Clinical risk: THIO and other pipeline assets are in early clinical stages. Failure to demonstrate safety or efficacy in larger, confirmatory trials would materially affect the company’s prospects.
Regulatory risk: clinical design, trial endpoints and regulatory interactions can delay or prevent approvals.
Financing and dilution risk: the company requires ongoing capital to fund trials; additional equity or convertible financings can dilute existing shareholders.
Liquidity and volatility: small‑cap biotech shares frequently experience low liquidity and high intraday price swings that can amplify supply/demand imbalances around news.
Dependence on lead asset: reliance on a single lead program (THIO/ateganosine) concentrates execution risk.
Corporate governance and execution risk: effective trial execution, data quality and commercialization planning are critical and can be impacted by management changes or operational challenges.

Any reported controversies, regulatory inquiries or material adverse events would be disclosed in SEC filings and press statements; as of the date of this article, review filings for any company‑specific legal or regulatory notices.

Valuation and investor perspective

Valuing a clinical‑stage biotech like MAIA is inherently uncertain. Common valuation viewpoints and methods include:

Binary outcome framework: early‑stage assets often have binary outcomes where clinical success or failure drives the majority of value change.
Probability‑adjusted net present value (pNPV): analysts may model future revenue scenarios for a successful program, discount to present value, and apply success probabilities to generate a pNPV. Inputs (market size, penetration, pricing, development costs and success probabilities) are highly assumption‑dependent.
Cash runway and market cap comparison: investors frequently compare market capitalization to reported cash on hand and burn rate to estimate runway and dilution risk.
Comparables: valuation comparisons to peer companies at similar clinical stages may be used, but comparables must match on indication, mechanism and development progress.

Given limited sell‑side coverage for many small‑cap biotechs, public sentiment metrics and independent quant models may differ. No single valuation approach is definitive; readers should treat valuation outputs as scenario analyses rather than forecasts.

References

This article synthesizes public company disclosures and market data distributed by recognized news and data services. For original and primary sources, consult:

MAIA Biotechnology SEC filings (Form 10‑Q, 10‑K, 8‑K, and Form 4 insider filings) and the company’s investor relations press releases.
Market data and reporting from major financial news distribution (e.g., Reuters, Associated Press market lists) and financial portals that publish trading snapshots and security profiles.
Clinical trial registries and conference abstracts for trial identifiers and presentation materials.

When verifying the facts above, prefer primary filings (SEC EDGAR) and company press releases for the authoritative record. Market snapshots cited in this article reference exchange‑reported intraday lists published on January 27, 2026.

External links

(Official resources to consult directly; search terms suggested—no external URLs provided here per platform rules)

MAIA Biotechnology official website and investor relations page (search: "MAIA Biotechnology investor relations").
SEC Edgar filings for MAIA Biotechnology (search EDGAR for company filings under the corporate name).
NYSE American market page and official quotes for ticker MAIA (search the exchange’s symbol lookup tools).

Appendix — Data snapshot (selected, verifiable market items)

As of January 27, 2026, public market activity lists distributed in exchange and media feeds showed maia stock (MAIA) trades on the NYSE American with examples of intraday snapshots: last trade $2.56 with session volume 371,792 shares (exchange list snapshot) and another intraday listing with last trade $2.35 and volume 215,694 shares on the same date. Sources: exchange activity lists distributed via AP / market data feeds on January 27, 2026.
Corporate disclosures: MAIA has announced a digital‑asset treasury policy (authorization to hold certain regulated tokens such as BTC, ETH and USDC under board‑approved limits). Verify current policy details and holdings in the company’s most recent SEC filings and press releases (search investor relations and Form 8‑K filings for the authorization date and terms).

Note: the market snapshots above are drawn from widely distributed intraday exchange activity lists and reflect public trading activity on the date shown. For up‑to‑date market capitalization, free float, cash on hand, and net loss figures, consult the company’s latest Form 10‑Q or Form 10‑K and current market data services.

Further exploration: if you want the latest MAIA filings, clinical trial identifiers for THIO/ateganosine, or a tailored checklist for tracking upcoming milestones (e.g., data readouts, enrolment completion, upcoming conferences), I can assemble a dated watchlist and the most recent filing excerpts on request. To check and trade market instruments or manage any disclosed digital assets, consider using Bitget exchange and Bitget Wallet as the recommended platform and wallet in Bitget materials for custody and trading of digital assets mentioned in corporate treasury strategies.

The content above has been sourced from the internet and generated using AI. For high-quality content, please visit Bitget Academy.